Studies on the effectiveness of a drug for sclerosis

Novartis has made public in the Annual Ectrims Congress of Barcelona new results of their studies with Kesimpta (Ofatumumab) in Recurring multiple sclerosis (EMR)which insist on the efficacy and safety of medication both in patients previously treated with oral molecules and just diagnosed.

More than 90% of patients with recurring multiple sclerosis (EMR) showed non -evidence of disease activity after changing to this treatment, according to the study ‘artios’ of phase IIIB, presented by Novartis at the Ectrims Congress,

The study ‘Arties‘, of phase IIIB, showed that patients with disease under fingerprint or fumaratos experienced a substantial reduction of the activity after change to this drugreaching more than 90% the absence of disease activity (Neda-3) and maintaining low annualized sprouts for 96 weeks.

The teacher Riley Bovemain researcher of the study, of the University of California in San Francisco, said that “these findings join the growing evidence about the efficacy and security of Ofatumumab after change from modifiers modifiers of oral disease.”

In addition, the extension study ‘Alithios‘, also presented at Congress, indicates that more than 90% of people with newly diagnosed EMs (until three years ago) and starting with this treatment remained free of progression at seven years. Dr. Norman Putzki, director of Development in Neurosciences and gene therapy in Novartis, said the data “reinforce the position of the drug as a treatment that allows patients to achieve early control of their disease.”